Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour

BJU International

Volumn 99, Issue 5, 2007, Pages 993-997

  Shayegan, Bobby ^a   Carver, Brett S ^a,b   Stasi, Jason ^a   Motzer, Robert J ^a   Bosl, George J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

Author keywords

Chemotherapy; Germ cell tumour; RPLND; Surgery

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FIBROSIS; FOLLOW UP; GERM CELL TUMOR; HISTOLOGY; HORMONE BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON SEMINOMATOUS GERMINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TERATOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; RETROPERITONEAL SPACE; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 34247126468     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06740.x     Document Type: Article

References (14)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-53
2. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387-91
3. Scher H, Bosl G, Geller N, Cirrincione C, Whitmore W, Golbey R. Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. Urology 1983; 21: 559-61
4. Stoter G, Sylvester R, Sleijfer DT et al. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res 1987; 47: 2714-8
5. Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 1997; 9: 207-9
6. Donohue JP, Einhorn LH, Williams SD. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 1980; 123: 876-80
7. Steyerberg EW, Keizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13: 1177-87
8. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol 2002; 20: 262-71
9. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 3310-7
10. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995; 13: 1170-6
11. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001; 19: 2647-57
12. Stenning SP, Parkinson MC, Fisher C et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party Cancer 1998; 83: 1409-19
13. Steyerberg EW, Keizer HJ, Zwartendijk J et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 1993; 68: 195-200
14. Motzer RJ, Amsterdam A, Prieto V et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159: 133-8